Pre-earnings brief
Reports
Mon, Oct 19, 2026
Est. EPS
$-0.21
Est. revenue
$0M
Implied move
±8.7%
EPS beat rate
88%
Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines to treat serious diseases. With a market cap of $14 billion, it operates in the health care sector, which is increasingly important as the demand for new therapies grows.
Last quarter
In Q2 2026, Summit Therapeutics reported an EPS of -$0.19, which was better than the expected -$0.26, resulting in a stock increase of 1.63% the following day. The company continues to show positive surprises in earnings.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+21.04%
Avg 1-day reaction
-3.44%
Overall, expectations are mixed as there are no analyst estimates available. However, the company has a strong history of beating EPS estimates.
Bull case
If Summit Therapeutics can continue its trend of beating EPS estimates, it may see a significant stock price increase, especially if any positive news about product development is announced.
Bear case
Conversely, if the company fails to meet expectations or reports disappointing news regarding its drug pipeline, it could lead to a sharp decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given Summit's history of beating EPS estimates, the actual EPS figure will be critical in determining market reaction.
Q2
What updates will be provided on the drug pipeline?
Any news regarding the progress or setbacks in their drug development could significantly impact investor sentiment.
—
Est. EPS
$1.94
Est. Rev
$188M
Impl. Move
±4.9%
Why consensus could be wrong
The Street may be underestimating Summit's ability to surprise on the upside given its recent track record of beating EPS estimates.
Supporting evidence
Summit has an 88% EPS beat rate over the last eight quarters.
The options market is pricing in a significant move, suggesting that traders expect volatility.
Recent earnings surprises have led to positive stock reactions, indicating investor confidence.
Key risk
If the EPS comes in better than expected, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for continued earnings surprises against the backdrop of product development updates.
Bull confirmed if
An EPS of -$0.15 or better would confirm the bull case.
Bear confirmed if
An EPS worse than -$0.25 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±20.75%
Historical Avg
±5.4%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±8.7% while SMMT has averaged ±5.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
68.6%
Smart-money positioning from the most recent 13F filings.
Institutional
17.58%
of float
Insider
80.89%
of float
Holders
330
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
32,786,348 sh · $588.5M
4.11%
-9.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Summit beats expectations, history suggests a potential stock increase of around 3% on the first day.
In line / cautious
If results are in line with expectations, the stock may remain relatively stable, reflecting cautious investor sentiment.
Miss
If the company misses expectations, history indicates a potential decline of about 1.43% on the first day.
The lines on the call that would change the story.
FMR, LLC
10,043,947 sh · $180.3M
1.26%
-7.5%
State Street Corporation
9,536,796 sh · $171.2M
1.20%
35.7%
Blackrock Inc.
9,529,041 sh · $171.0M
1.19%
-1.3%
Vanguard Capital Management LLC
5,734,484 sh · $102.9M
0.72%
0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.